Ocugen, Inc.
Ocugen, Inc. (Nasdaq: OCGN) is a biotechnology company developing gene therapies and other treatments for inherited and degenerative retinal diseases, as well as cell therapies and vaccines. Its modifier gene therapy platform uses nuclear hormone receptor genes to target multiple disease pathways; its leading… From the company’s description.
Over the twelve months to Sep 30, 2026, Ocugen, Inc. reported revenue of $4.78M, down 11.0% from a year earlier, and a net loss of $65.36M. Operations used $63.69M in cash. In fiscal 2025, it reported revenue of $4.41M, up 8.8% from fiscal 2024, and a net loss of $67.85M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Ocugen, Inc. does
In the company’s own words
Ocugen, Inc. (Nasdaq: OCGN) is a biotechnology company developing gene therapies and other treatments for inherited and degenerative retinal diseases, as well as cell therapies and vaccines. Its modifier gene therapy platform uses nuclear hormone receptor genes to target multiple disease pathways; its leading candidates address retinitis pigmentosa, Stargardt disease and geographic atrophy. Ocugen also develops OCU200, a biologic candidate for diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration. Its regenerative medicine program includes NeoCart, an autologous cartilage implant for knee injuries, and its inhaled vaccine platform includes candidates for COVID-19 and seasonal influenza. The company’s pipeline also includes OCU500, OCU510 and OCU520 vaccine candidates. Ocugen’s programs span clinical development, including a Phase 3 trial for OCU400 and a Phase 2/3 trial for OCU410ST. In 2025, it transferred NeoCart-related assets to its wholly owned subsidiary OrthoCellix. Its website is www.ocugen.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- MALVERN, PA
- Fiscal year end
- December
- CIK
- 1372299
- SIC
- 2836
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Ocugen, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Ocugen, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Ocugen, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Ocugen, Inc.’s debt, $2.27M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 6.75%, maturing 2034 to 2034.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Ocugen, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Ocugen, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Ocugen, Inc.'s last four quarterly filings that the numbers alone won't show?”